Athira Pharma Stock Alpha and Beta Analysis
| ATHA Stock | USD 6.76 0.18 2.74% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Athira Pharma. It also helps investors analyze the systematic and unsystematic risks associated with investing in Athira Pharma over a specified time horizon. Remember, high Athira Pharma's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Athira Pharma's market risk premium analysis include:
Beta 0.79 | Alpha 0.93 | Risk 9.21 | Sharpe Ratio 0.13 | Expected Return 1.17 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Athira Pharma Backtesting, Athira Pharma Valuation, Athira Pharma Correlation, Athira Pharma Hype Analysis, Athira Pharma Volatility, Athira Pharma History and analyze Athira Pharma Performance. Athira Pharma Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Athira Pharma market risk premium is the additional return an investor will receive from holding Athira Pharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Athira Pharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Athira Pharma's performance over market.| α | 0.93 | β | 0.79 |
Athira Pharma expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Athira Pharma's Buy-and-hold return. Our buy-and-hold chart shows how Athira Pharma performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Athira Pharma Market Price Analysis
Market price analysis indicators help investors to evaluate how Athira Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Athira Pharma shares will generate the highest return on investment. By understating and applying Athira Pharma stock market price indicators, traders can identify Athira Pharma position entry and exit signals to maximize returns.
Athira Pharma Return and Market Media
The median price of Athira Pharma for the period between Wed, Oct 8, 2025 and Tue, Jan 6, 2026 is 4.19 with a coefficient of variation of 25.42. The daily time series for the period is distributed with a sample standard deviation of 1.18, arithmetic mean of 4.65, and mean deviation of 0.85. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Key metrics from Athira Pharma Inc.s quarterly data - July 2025 Weekly Recap Fast Entry High Yield Stock Tips - newser.com | 10/16/2025 |
2 | ATHA Announces Filing of a Final Short Form Prospectus | 10/31/2025 |
3 | Will Athira Pharma Inc. stock benefit from AI adoption - Weekly Profit Summary Free Weekly Watchlist of Top Performers - newser.com | 11/03/2025 |
4 | Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update | 11/06/2025 |
5 | Will Athira Pharma Inc. stock benefit from AI adoption - Trade Performance Summary Weekly Breakout Opportunity Watchlist - newser.com | 11/10/2025 |
6 | Update Recap Is Athira Pharma Inc. stock ready for breakout - Bull Run Daily Chart Pattern Signal Reports - Fundao Cultural do Par | 11/14/2025 |
7 | How Athira Pharma Inc. stock performs during Fed tightening cycles - Market Growth Review High Conviction Investment Ideas - newser.com | 11/18/2025 |
8 | Acquisition by San Martin Javier of 46667 shares of Athira Pharma subject to Rule 16b-3 | 12/17/2025 |
9 | Mizuho maintains Neutral on Athira Pharma stock after transformative deals - Investing.com | 12/19/2025 |
10 | Acquisition by Perceptive Advisors Llc of 329756 shares of Athira Pharma at 6.35 subject to Rule 16b-3 | 12/23/2025 |
11 | Acquisition by Worthington Mark of 34358 shares of Athira Pharma at 4.07 subject to Rule 16b-3 | 12/24/2025 |
12 | ATHA Energy Announces Grant of Compensation Securities | 01/02/2026 |
About Athira Pharma Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Athira or other stocks. Alpha measures the amount that position in Athira Pharma has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 | 2025 | 2026 (projected) | Current Ratio | 5.37 | 4.18 | 4.8 | 4.56 | Net Debt To EBITDA | 0.71 | 0.49 | 0.57 | 0.54 |
Athira Pharma Upcoming Company Events
As portrayed in its financial statements, the presentation of Athira Pharma's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Athira Pharma's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Athira Pharma's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Athira Pharma. Please utilize our Beneish M Score to check the likelihood of Athira Pharma's management manipulating its earnings.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Athira Pharma
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Athira Pharma Backtesting, Athira Pharma Valuation, Athira Pharma Correlation, Athira Pharma Hype Analysis, Athira Pharma Volatility, Athira Pharma History and analyze Athira Pharma Performance. For information on how to trade Athira Stock refer to our How to Trade Athira Stock guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Athira Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.